Correction to: Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer

被引：0
|
作者：
Puneet Saxena
Pawan Kumar Singh
Prabhat Singh Malik
Navneet Singh
机构：
[1] Postgraduate Institute of Medical Education and Research (PGIMER),Department of Pulmonary Medicine
[2] University of Health Sciences,Department of Pulmonary and Critical Care Medicine, Post Graduate Institute of Medical Sciences (PGIMS)
[3] All India Institute of Medical Sciences,Department of Medical Oncology, Dr. B.R.A.I.R.C.H
来源：
Current Treatment Options in Oncology | 2020年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The original version of this article unfortunately contained mistakes. In Table 2, under the column 'Lead to death' in Row 5 [CheckMate-026], the figures should read as '0.7' for Experimental Arm and '1.1' for Comparator. Right now, these are printed as 0.007 and 0.011 respectively.
引用
收藏
相关论文
共 50 条
  • [41] Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Wu, X.
    Cui, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S817 - S817
  • [42] First-Line Treatment of Driver-Negative Non-Small Cell Lung Cancer
    Kim, So Yeon
    Gettinger, Scott
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (03) : 557 - 573
  • [43] What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?
    Ricciuti, Biagio
    Awad, Mark M.
    CANCER JOURNAL, 2020, 26 (06): : 485 - 495
  • [44] Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer
    Niyongere, Sandrine
    Saltos, Andreas
    Gray, Jhanelle E.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S433 - S450
  • [45] Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice
    De Marinis, Filippo
    Barberis, Massimo
    Barbieri, Vito
    Marchiano, Alfonso
    Gasparini, Stefano
    Migliorino, Maria Rita
    Romano, Giampiero
    Spinnato, Francesca
    Vitiello, Fabiana
    Gridelli, Cesare
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (03) : 217 - 228
  • [46] Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
    Auclin, Edouard
    Benitez-Montanez, Jose
    Tagliamento, Marco
    Parisi, Francesca
    Gorria, Teresa
    Garcia-Campelo, Rosario
    Dempsey, Naomi
    Pinato, David J.
    Reyes, Roxana
    Albarran-Artahona, Victor
    Dall'Olio, Filippo
    Soldato, Davide
    Hendriks, Lizza
    Nana, Frank Aboubakar
    Tonneau, Marion
    Lopez-Castro, Rafael
    Nadal, Ernest
    Kazandjian, Suzanne
    Muanza, Thierry
    Blanc-Durand, Felix
    Fabre, Elizabeth
    Castro, Natalia
    Arasanz, Hugo
    Rochand, Adrien
    Besse, Benjamin
    Routy, Bertrand
    Mezquita, Laura
    LUNG CANCER, 2023, 178 : 116 - 122
  • [47] First-Line Systemic Therapy for Non-Small Cell Lung Cancer
    Heist, Rebecca S.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 59 - +
  • [48] First-line immunotherapy in advanced non-small-cell lung cancer
    Noronha, Vanita
    Mehta, Prashant
    Malik, Prabhat Singh
    Patel, Amol
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 461 - 462
  • [49] Non-small cell Lung Cancer Personalization of First-Line Therapy
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (05)
  • [50] Anti-PD1 or anti-PD-L1 antibodies alone or in combination with chemotherapy first-line treatment of advanced non-small cell lung cancer
    Zhang Xuexia
    Cai Xiaoping
    Zheng Hao
    THORACIC CANCER, 2022, 13 (07) : 1104 - 1105
12345